These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17276898)

  • 21. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.
    Netland J; DeDiego ML; Zhao J; Fett C; Álvarez E; Nieto-Torres JL; Enjuanes L; Perlman S
    Virology; 2010 Mar; 399(1):120-128. PubMed ID: 20110095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
    Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
    Sheahan T; Whitmore A; Long K; Ferris M; Rockx B; Funkhouser W; Donaldson E; Gralinski L; Collier M; Heise M; Davis N; Johnston R; Baric RS
    J Virol; 2011 Jan; 85(1):217-30. PubMed ID: 20980507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine.
    Luo F; Liao FL; Wang H; Tang HB; Yang ZQ; Hou W
    Virol Sin; 2018 Apr; 33(2):201-204. PubMed ID: 29541941
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.
    Kang X; Yang BA; Hu Y; Zhao H; Xiong W; Yang Y; Si B; Zhu Q
    Clin Vaccine Immunol; 2006 Aug; 13(8):953-7. PubMed ID: 16893997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.
    Lv H; Wu NC; Tsang OT; Yuan M; Perera RAPM; Leung WS; So RTY; Chan JMC; Yip GK; Chik TSH; Wang Y; Choi CYC; Lin Y; Ng WW; Zhao J; Poon LLM; Peiris JSM; Wilson IA; Mok CKP
    Cell Rep; 2020 Jun; 31(9):107725. PubMed ID: 32426212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro.
    Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S
    Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice.
    Nagata N; Iwata N; Hasegawa H; Fukushi S; Harashima A; Sato Y; Saijo M; Taguchi F; Morikawa S; Sata T
    Am J Pathol; 2008 Jun; 172(6):1625-37. PubMed ID: 18467696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates.
    Regla-Nava JA; Nieto-Torres JL; Jimenez-Guardeño JM; Fernandez-Delgado R; Fett C; Castaño-Rodríguez C; Perlman S; Enjuanes L; DeDiego ML
    J Virol; 2015 Apr; 89(7):3870-87. PubMed ID: 25609816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.
    Subbarao K; McAuliffe J; Vogel L; Fahle G; Fischer S; Tatti K; Packard M; Shieh WJ; Zaki S; Murphy B
    J Virol; 2004 Apr; 78(7):3572-7. PubMed ID: 15016880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
    Wang SF; Tseng SP; Yen CH; Yang JY; Tsao CH; Shen CW; Chen KH; Liu FT; Liu WT; Chen YM; Huang JC
    Biochem Biophys Res Commun; 2014 Aug; 451(2):208-14. PubMed ID: 25073113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs.
    Ishii K; Hasegawa H; Nagata N; Mizutani T; Morikawa S; Suzuki T; Taguchi F; Tashiro M; Takemori T; Miyamura T; Tsunetsugu-Yokota Y
    Virology; 2006 Aug; 351(2):368-80. PubMed ID: 16678878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
    Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
    Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
    Du L; Zhao G; Chan CC; Sun S; Chen M; Liu Z; Guo H; He Y; Zhou Y; Zheng BJ; Jiang S
    Virology; 2009 Oct; 393(1):144-50. PubMed ID: 19683779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
    Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
    Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.